12:00 AM
 | 
Apr 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nipent pentostatin: Phase I/II data; marketed to treat hairy cell leukemia

In a U.S. Phase I/II trial, 6 of 9 patients with GvHD refractory to steroids and other standard salvage therapies responded to Nipent, giving an...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >